Related Experiment Video
Updated: Jul 10, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Hypofractionated accelerated radiochemotherapy with cytoprotection (Chemo-HypoARC) for inoperable non-small cell lung
Michael I Koukourakis1, George Patlakas, Marios E Froudarakis
1Department of Radiotherapy/Oncology, Democritus University of Thrace, Medical School, Alexandroupolis, Greece. targ@her.forthnet.gr
Background:
Concurrent radiochemotherapy and altered radiotherapy fractionation are under thorough investigation in locally advanced non-small cell lung carcinoma (NSCLC).
Patients And Methods:
The efficacy and tolerance of hypofractionated accelerated radiochemotherapy supported with high dose (up to 1000 mg daily) amifostine cytoprotection (hypoARC) was examined in 31 patients. Fifteen fractions of 3.5 Gy were delivered within 28-35 days. Liposomal doxorubicin and oxaliplatin were concurrently given.
Results:
A total of 65% of patients tolerated a daily amifostine dose of 750-1000 mg. Chemotherapy had an excellent tolerance. Grade 3 oesophagitis was noted in 7/31 (22.5%) patients. Radiation pneumonitis was absent and radiation fibrosis minimal. Complete and partial response were observed in 12/31 (38.6%) and 17/31 (54.8%) patients, respectively. The 2-year estimated local progression-free and overall survival interval were 58% and 45%, respectively.
Conclusion:
Given the simplicity of HypoARC, the very low morbidity, and the high complete response and survival rates obtained, HypoARC regimens deserve further testing.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...